Published in Eur J Clin Microbiol Infect Dis on December 01, 2005
Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag (2006) 0.82
The management of infections due to drug-resistant gram-positive bacteria. Eur J Clin Microbiol Infect Dis (2005) 0.81
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis (1999) 19.52
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 12.04
Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet (2002) 10.26
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med (1999) 10.06
Ventilator-associated pneumonia. Am J Respir Crit Care Med (2002) 9.63
Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep (2002) 7.34
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med (2005) 6.14
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Community-acquired pneumonia. N Engl J Med (1995) 6.12
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother (1996) 5.68
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64
Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med (1991) 5.63
Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep (1997) 5.30
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA (2003) 4.84
Methicillin-resistant staphylococcus aureus infections among competitive sports participants--Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep (2003) 4.14
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet (1998) 4.08
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis (2003) 3.39
Methicillin-resistant Staphylococcus aureus infections in correctional facilities---Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep (2003) 3.35
National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control (1996) 3.33
Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis (2003) 2.99
Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis (1999) 2.81
Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis (2000) 2.63
Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med (1998) 2.62
Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med (2001) 2.35
Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust (2001) 2.33
Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med (2004) 2.30
A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest (2004) 2.26
Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med (1996) 2.23
The prevention of ventilator-associated pneumonia. N Engl J Med (1999) 2.18
Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol (2000) 2.16
The Staphylococcus aureus "superbug". J Clin Invest (2004) 1.81
Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr Med J (2000) 1.79
Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb Mortal Wkly Rep (2000) 1.77
Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med (1994) 1.72
Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother (1998) 1.70
Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol (2005) 1.65
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother (1999) 1.65
Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother (1993) 1.51
Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother (2004) 1.43
Community-associated methicillin-resistant Staphylococcus aureus infections in Pacific Islanders--Hawaii, 2001-2003. MMWR Morb Mortal Wkly Rep (2004) 1.41
Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol (2001) 1.38
Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest (2001) 1.28
Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents (2005) 1.27
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm (2000) 1.12
Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med (2001) 1.12
Combination of flucloxacillin and gentamicin inhibits toxic shock syndrome toxin 1 production by Staphylococcus aureus in both logarithmic and stationary phases of growth. Antimicrob Agents Chemother (1997) 1.03
Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP (1991) 1.03
Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999. MMWR Morb Mortal Wkly Rep (2001) 1.01
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med (2000) 1.00
Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother (2004) 1.00
Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels. Ther Drug Monit (1995) 0.93
In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother (2004) 0.92
Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother (2004) 0.89
The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland. J Antimicrob Chemother (2002) 0.81